Pipeline


ONCOLOGY
Tivantinib (ARQ 197)⁷	C-Met Inhibitor	Daiichi Sankyo⁴ Kyowa Hakko⁵
ARQ 621	Eg5 Inhibitor
ARQ 736	BRAF Inhibition
ARQ 087	FGFR Inhibition
Non-ATP Competitive Kinase Inhibitors	Arqule Kinase Inhibitor Platform (AKIP^TM)	Daiichi Sankyo⁶
Portfolio Updated August 2011 ¹ Pre-GLP toxicology testing ² Post-initiation of GLP toxicology testing ³ Designation follows initation of first patient enrollment and dosing ⁴ U.S., Europe, South America and the rest of the world, excluding Japan and select Asian countries ⁵ Japan and select Asian countries ⁶ Two targets in oncology; other applications for additional collaborations under consideration ⁷ See corporate slide presentation here for the status of all ongoing trials with ARQ 197.